EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Bronchodilator and Anti‐Inflammatory Effect of Long‐Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper

I Agache iD, I M Adcock iD, C A Akdis iD, M Akdis, G Bentabol-Ramos, M van den Berge, C Boccabella iD, W G Canonica, C Caruso iD, M Couto iD, I Davila, D Drummond und 21 weitere

Allergy · 2025

DOI: 10.1111/all.16436 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergy, 2025. Verfasst von I Agache und 32 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Transylvania University, Brasov, Romania. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Asthma, Bronchodilator Agents, Muscarinic Antagonists. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 113 Literaturangaben. Gefördert von: European Academy of Allergy and Clinical Immunology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As cholinergic innervation is a major contributor to increased vagal tone and mucus secretion, inhaled long‐acting muscarinic antagonists (LAMA) are a pillar for the treatment of chronic obstructive pulmonary disease and asthma. By blocking the muscarinic receptors expressed in the lung, LAMA improve lung function and reduce exacerbations in asthma patients who remained poorly controlled despite treatment with inhaled corticosteroids and long‐acting β2 agonists. Asthma guidelines recommend LAMA as a third controller to be added on before the initiation of biologicals. In addition to bronchodilation, LAMA also exert anti‐inflammatory and anti‐fibrotic effects by inhibiting muscarinic receptors present in neutrophils, macrophages, fibroblasts and airway smooth muscle cells. Thus, besides bronchodilation, LAMA might provide additional therapeutic effects, thereby supporting an endotype‐driven approach to asthma management. The Position Paper, developed by the Asthma Section of the European Academy of Allergy and Clinical Immunology, discusses the main cholinergic pathways in the lung, reviews the findings of significant clinical trials and real‐life studies on LAMA use in asthma, examines the placement of these drugs in asthma clinical guidelines, and considers the potential for personalised medicine with LAMA in both adult and paediatric asthma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory AgentsAsthmaBronchodilator AgentsMuscarinic AntagonistsAnimalsHumansAcetylcholineMuscarinePulmonary Disease, Chronic ObstructiveSocieties, MedicalTime Factors

Stichwörter der Autor:innen

acetylcholineasthmabronchodilatorendotypelong‐acting muscarinic antagonistsprecision medicine

Substanzen

AcetylcholineAnti-Inflammatory AgentsBronchodilator AgentsMuscarineMuscarinic Antagonists

Autor:innen und Institutionen

  • Faculty of Medicine, Transylvania University, Brasov, Romania.
  • Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK.
  • Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.
  • Pulmonology Unit, Hospital Regional Universitario de Malaga and IBIMA-Plataforma BIONAND, Malaga, Spain.
  • Department of Pulmonary Diseases, Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.

ORCID-Profile: I Agache, I M Adcock, C A Akdis, C Boccabella, C Caruso, M Couto, A Gherasim, D J Jackson, M Jutel, S Loukides, M Mukherjee, O Palomares, A Papi, L Perez de Llano, O J Price, M H Shamji, D Shaw, M J Torres, I Eguiluz-Gracia

Förderung

  • European Academy of Allergy and Clinical Immunology

Zitieren

APA

Agache, I., Adcock, I. M., Akdis, C. A., Akdis, M., Bentabol-Ramos, G., van den Berge, M., Boccabella, C., Canonica, W. G., Caruso, C., Couto, M., Davila, I., Drummond, D., Fonseca, J., Gherasim, A., Del Giacco, S., Jackson, D. J., Jutel, M., Licari, A., Loukides, S., …, & Eguiluz-Gracia, I. (2025). The Bronchodilator and Anti‐Inflammatory Effect of Long‐Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper. Allergy. https://doi.org/10.1111/all.16436

Vancouver

Agache I, Adcock IM, Akdis CA, Akdis M, Bentabol-Ramos G, van den Berge M, et al. The Bronchodilator and Anti‐Inflammatory Effect of Long‐Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper. Allergy. 2025. doi:10.1111/all.16436

BibTeX
@article{Agache2025,
  author = {Agache, I and Adcock, I M and Akdis, C A and Akdis, M and Bentabol-Ramos, G and van den Berge, M and Boccabella, C and Canonica, W G and Caruso, C and Couto, M and Davila, I and Drummond, D and Fonseca, J and Gherasim, A and Del Giacco, S and Jackson, D J and Jutel, M and Licari, A and Loukides, S and Moreira, A and Mukherjee, M and Ojanguren, I and Palomares, O and Papi, A and Perez de Llano, L and Price, O J and Rukhazde, M and Shamji, M H and Shaw, D and Sanchez-Garcia, S and Testera-Montes, A and Torres, M J and Eguiluz-Gracia, I},
  title = {The Bronchodilator and Anti‐Inflammatory Effect of Long‐Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16436}
}
Kostenlos starten →